The role of protein kinase C-alpha in hematologic malignancies

Acta Haematologica

Volumn 115, Issue 1-2, 2006, Pages 1-8

  Lahn, Michael ^a   Sundell, Karen ^a   Köhler, Gabriele ^b  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Acute myelogenous leukemia; Antisense oligonucleotide; Aprinocarsen; Non Hodgkin lymphoma; PKC ; Targeted agents

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APRINOCARSEN; CAMPTOTHECIN; PACLITAXEL; PROTEIN KINASE C ALPHA; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CARCINOGENESIS; CLINICAL TRIAL; CYTOGENETICS; ENZYME INHIBITION; HEMATOLOGIC MALIGNANCY; HISTOPATHOLOGY; HUMAN; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; LYMPHOMA, NON-HODGKIN; NEOPLASM PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN KINASE C-ALPHA;

EID: 31144449363     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089458     Document Type: Review

References (65)

1. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
2. Piller G: Leukaemia - a brief historical review from ancient times to 1950. Br J Haematol 2001;112:282-292.
3. Peggs K, Mackinnon S: Imatinib mesylate - the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003;348:1048-1050.
4. Dancey J, Sausville EA: Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003;2:296-313.
5. Lahn M, Sundell K, Moore S: Targeting protein kinase C-alpha (PKC-alpha) in cancer with the phosphorothioate antisense oligonucleotide aprinocarsen. Ann NY Acad Sci 2003;1002:263-270.
6. Monia BP, Holmlund J, Dorr FA: Antisense approaches for the treatment of cancer. Cancer Invest 2000;18:635-650.
7. Couzin J: Cancer Drugs. Smart weapons prove tough to design. Science 2002;298:522-525.
8. Basu A: The potential of protein kinase C as a target for anticancer treatment. Pharmacol Ther 1993;59:257-280.
9. Newton AC: Regulation of protein kinase C. Curr Opin Cell Biol 1997;9:161-167.
10. Nishizuka Y: The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988;334:661-665.
11. Martelli AM, Sang N, Borgatti P, Capitani S, Neri LM: Multiple biological responses activated by nuclear protein kinase C. J Cell Biochem 1999;74:499-521.
12. Blobe GC, Obeid LM, Hannun YA: Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev 1994;13:411-431.
13. Cornford P, Evans J, Dodson A, Parsons K, Woolfenden A, Neoptolemos J, Foster CS: Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. Am J Pathol 1999;154:137-144.
14. Denham DW, Franz MG, Denham W, Zervos EE, Gower WR Jr, Rosemurgy AS, Norman J: Directed antisense therapy confirms the role of protein kinase C-alpha in the tumorigenicity of pancreatic cancer. Surgery 1998;124:218-223; discussion 223-224.
15. Gescher A: Towards selective pharmacological modulation of protein kinase C - opportunities for the development of novel antineoplastic agents. Br J Cancer 1992;66:10-19.
16. Kopp R, Noelke B, Sauter G, Schildberg FW, Paumgartner G, Pfeiffer A: Altered protein kinase C activity in biopsies of human colonic adenomas and carcinomas. Cancer Res 1991; 51:205-210.
17. La Porta CA, Tessitore L, Comolli R: Changes in protein kinase C alpha, delta and in nuclear beta isoform expression in tumour and lung metastatic nodules induced by diethylnitrosamine in the rat. Carcinogenesis 1997;18:715-719.
18. O'Brian C, Vogel VG, Singletary SE, Ward NE: Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res 1989;49:3215-3217.
19. O'Brian C, Kuo J: Protein kinase C inhibitors; in Kuo J (ed): Protein Kinase C. New York, Oxford University Press, 1994, pp 96-120.
20. Shen L, Dean NM, Glazer RI: Induction of p53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma multiforme cells by a protein kinase Cα antisense oligonucleotide. Mol Pharmacol 1999;55:396-402.
21. Wang XY, Repasky E, Liu HT: Antisense inhibition of protein kinase Cα reverses the transformed phenotype in human lung carcinoma cells. Exp Cell Res 1999;250:253-263.
22. Ahmad S, Trepel JB, Ohno S, Suzuki K, Tsuruo T, Glazer RI: Role of protein kinase C in the modulation of multidrug resistance: expression of the atypical gamma isoform of protein kinase C does not confer increased resistance to doxorubicin. Mol Pharmacol 1992;42:1004-1009.
23. Gill PK, Gescher A, Gant TW: Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes alpha and theta. Eur J Biochem 2001;268:4151-4157.
24. Gravitt KR, Ward NE, Fan D, Skibber JM, Levin B, O'Brian CA: Evidence that protein kinase C-alpha activation is a critical event in phorbol ester-induced multiple drug resistance in human colon cancer cells. Biochem Pharmacol 1994;48:375-381.
25. Gupta KP, Ward NE, Gravitt KR, Bergman PJ, O'Brian CA: Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoylated protein kinase C-alpha pseudosubstrate peptide. J Biol Chem 1996;271: 2102-2111.
26. Swannie HC, Kaye SB: Protein kinase C inhibitors. Curr Oncol Rep 2002;4:37-46.
27. Leitges M, Plomann M, Standaert ML, Bandyopadhyay G, Sajan MP, Kanoh Y, Farese RV: Knockout of PKC alpha enhances insulin signaling through PI3K. Mol Endocrinol 2002;16:847-858.
28. Society AC: Cancer Facts and Figures: 2004. Atlanta, American Cancer Society, 2004.
29. Freedman A, Nadler L: Malignancies of lymphoid cells; in Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL (eds): Harrison's Principles of Internal Medicine. New York, McGraw-Hill, 1998, pp 695-712.
30. Levine EG, Arthur DC, Frizzera G, Peterson BA, Hurd DD, Bloomfield CD: Cytogenetic abnormalities predict clinical outcome in non-Hodgkin lymphoma. Ann Intern Med 1988;108:14-20.
31. Schouten HC, Sanger WG, Weisenburger DD, Anderson J, Armitage JO: Chromosomal abnormalities in untreated patients with non-Hodgkin's lymphoma: associations with histology, clinical characteristics, and treatment outcome. The Nebraska Lymphoma Study Group. Blood 1990;75:1841-1847.
32. Rodriguez MA, Ford RJ, Goodacre A, Selvanayagam P, Cabanillas F, Deisseroth AB: Chromosome 17- and p53 changes in lymphoma. Br J Haematol 1991;79:575-582.
33. Offit K, Jhanwar SC, Ladanyi M, Filippa DA, Chaganti RS: Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment. Genes Chromosom Cancer 1991;3:189-201.
34. Jendiroba D, Younes A, Katz R, Hill D, Cabanillas F, Andreeff M: Chromosome 17 numerical abnormalities in 55 patients with non-Hodgkin's lymphoma: a fluorescence in situ hybridization study. Leukemia 1995;9:1144-1146.
35. Garban F, Truman JP, Lord J, Drenou B, Plumas J, Jacob MC, Sotto JJ, Charron D, Mooney N: Signal transduction via human leucocyte antigen class II molecules distinguishes between cord blood, normal, and malignant adult B lymphocytes. Exp Hematol 1998;26:874-884.
36. Flaishon L, Lantner F, Hershkoviz R, Levo Y, Shachar I: Low levels of IFN-gamma down-regulate the integrin-dependent adhesion of B cells by activating a pathway that interferes with cytoskeleton rearrangement. J Biol Chem 2001;276:46701-46706.
37. Keenan C, Thompson S, Knox K, Pears C: Protein kinase C-alpha is essential for Ramos-BL B cell survival. Cell Immunol 1999;196:104-109.
38. Kelly ML, Tang Y, Rosensweig N, Clejan S, Beckman BS: Granulocyte-macrophage colony-stimulating factor rescues TF-1 leukemia cells from ionizing radiation-induced apoptosis through a pathway mediated by protein kinase Cα. Blood 1998;92:416-424.
39. Ohmi Y, Ohta A, Sasakura Y, Sato N, Yahata T, Santa K, Habu S, Nishimura T: The role of phorbol ester-sensitive protein kinase C isoforms in lymphokine-activated killer cell-mediated cytotoxicity: dissociation between perforin-dependent and Fas-dependent cytotoxicity. Biochem Biophys Res Commun 1997;235:461-464.
40. Bianchi A, Mariani S, Beggiato E, Borrione P, Peola S, Boccadoro M, Pileri A, Massaia M: Distribution of T-cell signalling molecules in human myeloma. Br J Haematol 1997;97:815-820.
41. Podar K, Tai YT, Lin BK, Narsimhan RP, Sattler M, Kijima T, Salgia R, Gupta D, Chauhan D, Anderson KC: Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem 2002;277:7875-7881.
42. Keating MJ, Cork A, Broach Y, Smith T, Walters RS, McCredie KB, Trujillo J, Freireich EJ: Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leuk Res 1987;11:119-133.
43. Keating MJ, Smith TL, Kantarjian H, Cork A, Walters R, Trujillo JM, McCredie KB, Gehan EA, Freireich EJ: Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 1988;2:403-412.
44. Swansbury GJ, Lawler SD, Alimena G, Arthur D, Berger R, Van den Berghe H, Bloomfield CD, de la Chappelle A, Dewald G, Garson OM, et al: Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 1994;73:1-7.
45. Larson RA, Le Beau MM, Vardiman JW, Testa JR, Golomb HM, Rowley JD: The predictive value of initial cytogenetic studies in 148 adults with acute nonlymphocytic leukemia: a 12-year study (1970-1982). Cancer Genet Cytogenet 1983;10:219-236.
46. Manzel L, Macfarlane DE: Protein kinase C is not necessary for transforming growth factor beta-induced growth-arrest in leukemia cell lines. Leuk Res 1997;21:403-410.
47. Komada F, Nishikawa M, Uemura Y, Morita K, Hidaka H, Shirakawa S: Expression of three major protein kinase C isozymes in various types of human leukemic cells. Cancer Res 1991;51:4271-4278.
48. Kornblau SM, Vu HT, Ruvolo P, Estrov Z, O'Brien S, Cortes J, Kantarjian H, Andreeff M, May WS: BAX and PKCα modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res 2000;6: 1401-1409.
49. Devalia V, Thomas NS, Roberts PJ, Jones HM, Linch DC: Down-regulation of human protein kinase C alpha is associated with terminal neutrophil differentiation. Blood 1992;80:68-76.
50. Balasubramanian N, Advani SH, Zingde SM: Protein kinase C isoforms in normal and chronic myeloid leukemic neutrophils. Distinct signal for PKC alpha by immunodetection on PVDF membrane, decreased expression of PKC alpha and increased expression of PKC delta in leukemic neutrophils. Leuk Res 1998;22:597-604.
51. Berry DM, Meckling-Gill KA: Vitamin D analogs, 20-Epi-22-oxa-24a,26a,27a, -trihomo-1α,25(OH)2-vitamin D3, 1,24(OH)2-22-ene-24-cyclopropyl-vitamin D3 and 1α,25(OH)-2-lumisterol3 prime NB4 leukemia cells for monocytic differentiation via nongenomic signaling pathways, involving calcium and calpain. Endocrinology 1999;140:4779-4788.
52. Kang JH, Shin I, Han JS: Changes of phospholipase D activity in TNF-alpha and anti-Fas/Apo1 monoclonal antibody induced apoptosis in HL-60 and A20 cells. Exp Mol Med 1998;30:21-27.
53. Edashige K, Sato EF, Akimaru K, Kasai M, Utsumi K: Differentiation of HL-60 cells by phorbol ester is correlated with up-regulation of protein kinase C-alpha. Arch Biochem Biophys 1992;299:200-205.
54. Mallia CM, Jeter JR Jr, Fields AP, Wilson RB, Beckman BS: Protein kinase C beta from Friend erythroleukemia cells is associated with chromatin and DNA. Mol Cell Biochem 1995;151:107-111.
55. Emmanouilides C, Saleh A, Laufman L, Saven A, Harden E, Lister J: Phase II trial of the efficacy and safety of ISIS 3521/LY900003, an antisense inhibitor of PKC-alpha, in patients with low-grade, non-Hodgkin's lymphoma (abstract 1124). Proc ASCO 2002 Annu Meet.
56. Martelli AM, Bortul R, Bareggi R, Tabellini G, Grill V, Baldini G, Narducci P: The pro-apoptotic drug camptothecin stimulates phospholipase D activity and diacylglycerol production in the nucleus of HL-60 human promyelocytic leukemia cells. Cancer Res 1999;59:3961-3967.
57. Breyer I, Azzi A: Differential inhibition by alpha- and beta-tocopherol of human erythroleukemia cell adhesion: role of integrins. Free Radic Biol Med 2001;30:1381-1389.
58. Lahn M, Fisch P, Kohler G, Kunzmann R, Hentrich I, Jesuiter H, Behringer D, Muschal B, Veelken H, Kulmburg P, Ikle DN, Lindemann A: Pro-inflammatory and T cell inhibitory cytokines are secreted at high levels in tumor cell cultures of human renal cell carcinoma. Eur Urol 1999;35:70-80.
59. Lahn M, Kunzmann R, Kohler G, Ikle DN, Hentrich I, Jesuiter H, Kulmburg P, Veelken H, Mackensen A, Rosenthal F, Lindemann A: Comparison of cytogenetics, cytokine secretion, and oncogene expression in primary cultures of renal carcinoma cells. Oncology 1997;54:429-437.
60. Kontny E, Kurowska M, Szczepanska K, Maslinski W: Rottlerin, a PKC isozyme-selective inhibitor, affects signaling events and cytokine production in human monocytes. J Leukoc Biol 2000;67:249-258.
61. St-Denis A, Chano F, Tremblay P, St-Pierre Y, Descoteaux A: Protein kinase C-alpha modulates lipopolysaccharide-induced functions in a murine macrophage cell line. J Biol Chem 1998;273:32787-32792.
62. Lahn M, Paterson BM, Sundell K, Ma D: The role of protein kinase C-alpha (PKC-alpha) in malignancies of the gastrointestinal tract. Eur J Cancer 2004;40:10-20.
63. Nemunaitis J, Holmlund JT, Kraynak M, Richards D, Bruce J, Ognoskie N, Kwoh TJ, Geary R, Dorr A, Von Hoff D, Eckhardt SG: Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J Clin Oncol 1999;17:3586-3595.
64. Alizadeh A, Eisen M, Davis RE, Ma C, Sabet H, Tran T, Powell JI, Yang L, Marti GE, Moore DT, Hudson JR Jr, Chan WC, Greiner T, Weisenburger D, Armitage JO, Lossos I, Levy R, Botstein D, Brown PO, Staudt LM: The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol 1999;64:71-78.
65. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947.